Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.3 (market cap $41.13B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 19.2× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| IEF | RXRX | |
|---|---|---|
Market Cap | $41.13B | $2.14B |
Volume | 10,340,382 | 30,789,535 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $6.79 |
52-Week Low | $88.92 | $2.84 |
Typical Hold Time | 108 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.11, down 0.02% with a bearish technical outlook. The fund shows neutral oscillators but bearish moving averages, with RSI levels below 30 indicating potential oversold conditions. Recent dividend payments of $0.31-$0.33 provide income support amid market volatility. The bond market faces pressure from rising Treasury yields and inflation concerns.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current yields offer attractive entry points for income investors, persistent inflation and Fed policy uncertainty pose significant risks. Defensive positioning in fixed income suggests limited near-term upside potential.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
